Cited by 476T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 72 of the 73 references it cites were found in a registry or an index.

Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox

Open access

Oh, David Y., Fong, Lawrence·2021·Immunity

DOI 10.1016/j.immuni.2021.11.015PMC PMC8809482

Open this paper in CoChat — free account Open PDF

Abstract

Cytotoxic T cells are important effectors of anti-tumor immunity. While tumor killing is ascribed to CD8 + T cell function, pre-clinical and clinical studies have identified intra-tumoral CD4 + T cells that possess cytotoxic programs and can directly kill cancer cells. Cytotoxic CD4 + T cells are found in other disease settings including infection and autoimmunity. Here, we review the phenotypic and functional characteristics of cytotoxic CD4 + T cells in non-cancer and cancer contexts. We conduct a comparative examination of cytolytic mechanisms of cytotoxic CD4 + T cells across disease states and synthesize features that define these cells independent of context. We discuss regulatory mechanisms driving ontogeny and effector function and evidence for the clinical relevance of cytotoxic CD4 + T cells in cancer. In this context, we highlight important gaps in understanding in the biology of cytotoxic CD4 + T cells as well as the potential use of these cells in immunotherapies for specific cancers.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2021.11.015

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. The ontogeny and regulation of cytotoxic CD4+ T cells in cancer (A) A schematic of known CD4+ T cell functional subtypes, the cytokines that promote their differentiation, and master transcription factors (TFs) involved in their specification. As indicated, cytotoxic CD4+ T cells can arise from unpolarized Th0, Th1, or Th2 cells in response to IL-2 depending on the context; also, the contributions of the TFs RUNX3, TBET, BLIMP-1, and EOMES to specifying the cytotoxic CD4+ T cell state are also context-dependent, as discussed in the text. (B) Mechanisms that may contribute to activation of cytotoxic CD4+ T cells (red), anti-tumor cytotoxicity effector function (dark blue) including cytokines (light blue), as well as co-stimulatory (orange) or co-inhibitory (green) immune checkpoints are shown.CC BY · PubMed Central

Figure 2. Comparison of cytotoxic CD4+ T cell programs in cancer and non-cancer contexts Expression of key transcripts in cytotoxic CD4+ T cells in human and murine cancer, as well as human viral (dengue), murine viral (adenovirus), and human aging. Comparisons were made based on inspection of single-cell transcriptomic data, with the exception of bulk microarray data for murine cancer. Specific references for each dataset, and the platforms used for single-cell sequencing, are indicated. Lighter shading and question marks indicate where findings are inconsistent between datasets (e.g., comparing various human cancers).CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · cited 1×
“Interestingly, in a complementary approach where high-risk resected stage III or stage IV melanoma patients were immunized with pools of long peptides containing predicted neoantigens prioritized based solely on HLA-A or HLA-B predicted binding affinity, neoantigen-specific CD4+ T cell responses were seen in addition…”
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
Puram, S. V., Tirosh, I., Parikh, A. S., Patel, A. P., Yizhak, K., Gillespie, S., Rodman, C., Luo, C. L., Mroz, E. A., Emerick, K. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.044 · Cited by 2,557
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Azizi, E., Carr, A. J., Plitas, G., Cornish, A. E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.060 · Cited by 1,976
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
Guo, X., Zhang, Y., Zheng, L., Zheng, C., Song, J., Zhang, Q., Kang, B., Liu, Z., Jin, L., Xing, R., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0045-3 · Cited by 1,651
Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., Modak, M., Carotta, S., Haslinger, C., Kind, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.003 · Cited by 1,624
Lineage tracking reveals dynamic relationships of T cells in colorectal cancer
Zhang, L., Yu, X., Zheng, L., Zhang, Y., Li, Y., Fang, Q., Gao, R., Kang, B., Zhang, Q., Huang, J. Y., et al. (2018) · Nature · doi:10.1038/s41586-018-0694-x · Cited by 1,505
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N. H., Wallen, H. D., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R. M., Jungbluth, A. A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 904

Show all 73 references

Sorted by citations

Items 201–300 of 476

TIGIT Blockade Reshapes the Tumor Microenvironment Based on the Single-cell RNA-Sequencing Analysis
Lang, Y., Huang, H., Jiang, H., Wu, S., Chen, Y., Xu, B., Liu, Y., Zhu, D., Zheng, X. W., Chen, L., et al. (2024) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000511 · Cited by 6
“26,27 30 It has been widely reported that Tregs express high levels of TIGIT in the TME.”
Background
pH-responsive self-assembling peptides potentiate therapeutic efficacy via prolonged drug retention and immunomodulation
Peng, S., Yuan, X., Li, H., Huang, H., Li, C., Wei, C., Ren, J., Zhang, Q., Ding, G., & Bai, J. (2024) · Materials & Design · doi:10.1016/j.matdes.2024.112893 · Cited by 6
Exploiting aluminum-based metal-organic frameworks as dual-adjuvant delivery platforms for potentiated immune response of subunit vaccines
Pan, Y., Han, J., Wang, G., Zhong, T., Liu, S., Qi, Y., & Huang, Y. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.160128 · Cited by 8
Grain-sized moxibustion activates dendritic cells to enhance the antitumor immunity of cancer vaccines
Shen, W., Hu, D., Gong, C., Cheng, F., Luo, J., Wang, L., Yao, C., Wu, H., Zhao, C., & Zhu, S. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01134-w · Cited by 7
Purinergic signaling modulates CD4+ T cells with cytotoxic potential during Trypanosoma cruzi infection
Bergero, G., Mazzocco, Y. L., Rosso, S. D., Liu, R., Gallardo, Z. M. C., Robson, S. C., Rottenberg, M. E., & Aoki, M. P. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186785 · Cited by 6
“While cell-mediated cytotoxicity has traditionally been attributed to CD8 + T cells, recent studies have highlighted the role of cytotoxic CD4 + T cells in combating intracellular pathogens and tumors (21, 35).”
Targeting autophagy and plasminogen activator inhibitor-1 increases survival and remodels the tumor microenvironment in glioblastoma
Shifman, S. G., O’Connor, J. L., Radin, D. P., Sharma, A., Infante, L., Ferraresso, F., Kastrup, C. J., Lawrence, D. A., & Tsirka, S. E. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03473-w · Cited by 6
“This result suggests that MDI-2268 may support the development of a successful cancer immune response [45].”
The assembly of cancer-specific ribosomes by the lncRNA LISRR suppresses melanoma anti-tumor immunity
Cinque, S., Verheyden, Y., Adnane, S., Marino, A., Hanache, S., Vendramin, R., Cuomo, A., Poźniak, J., Calabuig, Á. C., Baldewijns, M. M. L. L., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20251507 · Cited by 8
HIV-seq reveals gene expression differences between HIV-transcribing cells from viremic and suppressed people with HIV
Frouard, J., Telwatte, S., Luo, X., Gill, N., Thomas, R., Arneson, D. V., Roychoudhury, P., Butte, A. J., Wong, J. K., Hoh, R., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68797-3 · Cited by 12
“Active viral replicationmaypromotetheacquisitionandmaintenanceof cytotoxic functions by CD4 +T cells by eliciting a sustained pro-in ﬂ ammatory environment, which has been shown in the context of cancer 70 as well as during in ﬂ uenza infection 71 .”
Identification of subtypes of hepatocellular carcinoma and screening of prognostic molecular diagnostic markers based on cell adhesion molecule related genes
Sun, R., Gao, Y., & Shen, F. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1042540 · Cited by 6
“David Y’s study showed that CD4T cells can also mediate cytotoxicity in cancer should lead to novel approaches to further enhance their direct anti-tumor activity in patients (Oh and Fong 2021).”
Background
A topic modeling approach reveals the dynamic T cell composition of peripheral blood during cancer immunotherapy
Peng, X., Lee, J., Adamow, M. J., Maher, C. A., Postow, M. A., Callahan, M. K., Panageas, K. S., & Shen, R. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100546 · Cited by 5
Terminally differentiated cytotoxic CD4 + T cells were clonally expanded in the brain lesion of radiation‐induced brain injury
Ma, X., Zuo, Y., Hu, X., Chen, S., Zhong, K., Xue, R., Gui, S., Liu, K., Li, S., Zhu, X., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14682 · Cited by 6
Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study
Lü, Z., Yin, Y., Rao, T., Xu, X., Zhao, K., Liu, Z., Qin, C., & Tang, M. M. (2024) · BMC Cancer · doi:10.1186/s12885-024-12196-8 · Cited by 6
“Additionally, scientific evidence supports the utilization of CD4/8 cells as an immunotherapeutic strategy for renal cell carcinoma (RCC) [24, 25].”
Background
The effect of smoking on tumor immunoediting: Friend or foe?
Jiang, Y., & Li, H. (2024) · Tobacco Induced Diseases · doi:10.18332/tid/189302 · Cited by 6
Integrating single-cell RNA-seq to identify fibroblast-based molecular subtypes for predicting prognosis and therapeutic response in bladder cancer
Wang, J., Tan, Z., Huang, Y., Li, C. H., Zhan, P., Wang, H., & Li, H. (2024) · Aging · doi:10.18632/aging.206021 · Cited by 6
Potential crosstalk between Naïve CD4+ T cells and SPP1+ Macrophages is associated with clinical outcome and therapeutic response in hepatocellular carcinoma
Dong, L., Qiu, X., Li, Z., Ge, W., Tang, X., Zhou, R., Chen, W., Xu, X., & Wang, K. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113231 · Cited by 7
NKG2D-mediated cytotoxicity of CD4 cytotoxic T cells in multiple myeloma
Kim, S., Kwak, J.-E., Koh, J., Lee, J. E., Kook, H. W., Kim, M., Chung, H., Kim, Y. R., Kim, S., Kim, J. S., et al. (2025) · Blood · doi:10.1182/blood.2024025875 · Cited by 7
Spatiotemporal and cell-state control of antigen presentation during tolerance and immunity
Hor, J. L., & Germain, R. N. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102357 · Cited by 6
Prediction of prognosis and immune landscape in cervical cancer based on heat shock protein-related genes
Wang, M., & Li, Z. (2023) · International Journal of Hyperthermia · doi:10.1080/02656736.2023.2259140 · Cited by 6
“T helper cells play a crucial role in the adaptive immune system by releasing cytokines and chemokines that promote the activity of other immune cells [43] and have been shown to have a direct cytotoxic effect on tumors in various types of cancer [44].”
Background
Attenuated Salmonella carrying siRNA-CD24 improved the effect of oxaliplatin on HCC
Li, B., Zhao, T., Shao, M., Cai, J., Chen, S., Chen, X., Yang, M., Zheng, Y., Cui, C., Guo, S., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111025 · Cited by 6
Prediction of Prognosis and Immunotherapy Response with a Novel Natural Killer Cell Marker Genes Signature in Osteosarcoma
Li, Q., Huang, X., & Zhao, Y. (2023) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2023.0103 · Cited by 6
Promising prognostic value of Transglutaminase type 2 and its correlation with tumor-infiltrating immune cells in skin cutaneous melanoma
Muccioli, S., Ciaccio, R., Brillo, V., & Leanza, L. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01087-1 · Cited by 6
“Among them, HLA-DMB [46], HLA-DRA [47], IL12A, and IL12B [48], whose determinant role in cancer outcome as immune adjuvants has already been published, are found in the top 500 TG2 positively correlating genes.”
Background
Comprehensive analysis of FRAS1/FREM family as potential biomarkers and therapeutic targets in renal clear cell carcinoma
Wang, G., Wang, Z., Lu, H., Zhao, Z., Guo, L., Kong, F., Wang, A., & Zhao, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.972934 · Cited by 6
“Therefore, immunotherapy approaches have shifted from only stimulating CD8 T cells to targeting and assessing CD4 subsets and increasing numbers of clinical studies have demonstrated that targeting CD4 T cells is safe and effective (Li T. et al., 2020; Cachot et al., 2021; Oh and Fong, 2021).”
Background
High-dimensional single-cell definition of CLL T cells identifies Galectin-9 as novel immunotherapy targetPreprint
Cid, L. L., Wong, J., Botana, I. F., Paul, Y., Wierz, M., Floerchinger, A., Gonder, S., Pagano, G., Chazotte, M., Bestak, K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.15.519719 · Cited by 6
Single cell transcriptome profiling of immune tissues from germ-free and specific pathogen-free piglet
Zhang, J., Tang, C., Liu, Y., Sun, J., Li, X., Long, K., Kong, F., Chen, S., Liang, H., Ding, Y., et al. (2025) · Scientific Data · doi:10.1038/s41597-025-04957-2 · Cited by 6
BHLHE40 drives protective polyfunctional CD4 T cell differentiation in the female reproductive tract against Chlamydia
Mercado, M. A. B., Li, Q., Quick, C. M., Kim, Y., Palmer, R., Huang, L., & Li, L. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011983 · Cited by 5
“The emerging roles of cytotoxic CD4 T cells have been demonstrated in a variety of infection models, autoimmune diseases and cancer [59,60].”
Background
Macrophage crosstalk and therapies: Between tumor cells and immune cells
Fan, C.-Y., Zheng, J.-S., Hong, L., & Ling, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113037 · Cited by 5
Helper ILCs in the human hematopoietic system
Su, X., Deng, Z., Lan, Y., Liu, B., & Liu, C. (2025) · Trends in Immunology · doi:10.1016/j.it.2025.01.009 · Cited by 5
BCL ‐2 Inhibitor Regulates Number, Function, and Antitumor Immunity of T Cells by Influencing Glycolysis in AML
Peng, X., Li, Y., Tang, F., Ma, Y., Bai, J. Y., Li, L., & Zhang, L. (2025) · Cancer Science · doi:10.1111/cas.70139 · Cited by 5
Lactate oxidase-integrated nanomaterials for tumor microenvironment modulation: Mechanisms and therapeutic applications
Xu, X., Chang, D., Cai, Y., Wang, J., Liu, J., Xu, P., & Ma, Y. (2025) · Nano Biomedicine and Engineering · doi:10.1016/j.nbe.2025.100001 · Cited by 5
Leveraging T cells for cancer immunotherapy
Bates, A., Fletcher, N. E., Gao, F., Pinho, M. P., & Dong, T. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00007-z · Cited by 8
“Although cytotoxic CD4 + T cells have been described [34], activated CD4 + T cells predominantly attract and support other immune cells within tumour draining lymph nodes and the tumour microenvironment (TME) [35].”
Activated CD38+ mast cells promote gastric cancer progression by suppressing CD8+ T cell cytotoxic activity through adenosine metabolism
Zhao, J., Feng, D., Zhang, F., Cai, S., Xiong, Y., Pan, G., Ma, J., Tan, J., Zhong, M., Lin, Z., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116863 · Cited by 6
Antigenic targets in clear cell renal cell carcinoma
Schindler, N. R., & Braun, D. A. (2023) · Kidney Cancer · doi:10.3233/kca-230006 · Cited by 6
Deciphering CD4+ T cell‐mediated responses against cancer
Kirkpatrick, C. A., & Lu, Y. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23730 · Cited by 6
Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsets
Liu, A., Zhang, G., Yang, Y., Xia, Y., Li, W., Liu, Y., Cui, Q., Wang, D., & Yu, J. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03738-x · Cited by 5
Overcoming GABA-Induced Treg Suppression of Immunity by ABAT to Augment CD8+T Cell Antitumor Immune Response in Liver Cancer
Han, H., Lu, Y., Xu, S., Zhang, W., Lin, W., Zhan, J., Chen, G., & Gu, B. (2024) · International Archives of Allergy and Immunology · doi:10.1159/000542404 · Cited by 5
“Yet, deeper insights into antitumor immune mechanisms have revealed that regulatory T cells (Tregs), a distinct subset of CD4 + T cells, can mediate immunosuppression within the TME, thereby enabling tumor immune evasion [6, 7].”
A high-throughput immunopeptidome platform for MHC II alleles to characterize antigen-specific CD4+ T cells
Chen, J., Zhu, X., Huo, J., Wu, S., Zhou, T., Cheng, C., Dong, H., Li, Y., Dong, X., & Chen, Y. (2025) · Biomedical Technology · doi:10.1016/j.bmt.2025.100112 · Cited by 5
Heat shock protein 90 C-terminal inhibitor PNSA promotes anticancer immunology of CD8+ T cells
Zhang, A., Li, M., Wang, Y., Xiong, Y., Zhu, T., Qi, X., & Li, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110471 · Cited by 5
Sex‐based immune microenvironmental feature heterogeneity in response to PD ‐1 blockade in combination with chemotherapy for patients with untreated advanced non‐small‐cell lung cancer
Yu, X., You, Z., Liu, Y., Fang, J., Zhao, Q., Sun, Z., Song, Y., Liu, J., & Sun, C. (2024) · Cancer Medicine · doi:10.1002/cam4.7423 · Cited by 5
Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth
Huo, J., Huang, Y., Zheng, Z. Y., Tay, X. N., Mahfut, F. B., Zhang, W., Lam, K., Yang, Y., & Xu, S. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac012 · Cited by 5
“This finding is consistent with recent findings that CD4 cytotoxic T cells are also important for anti-tumor immunity and have potential use in immunotherapy for specific cancers [34].”
Result
The Roles of RUNX Proteins in Lymphocyte Function and Anti-Tumor Immunity
Seo, W., Nomura, A., & Taniuchi, I. (2022) · Cells · doi:10.3390/cells11193116 · Cited by 5
The assembly of cancer-specific ribosomes by the lncRNA LISRR suppresses melanoma anti-tumour immunityPreprint
Cinque, S., Verheyden, Y., Adnane, S., Marino, A., Katopodi, V., Demesmaeker, E., Knezevic, Z., Hanache, S., Vendramin, R., Cuomo, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.06.523012 · Cited by 5
Single-Cell and Spatial Transcriptomic Analyses Deciphering the Three-Layer Architecture of Human Tuberculosis GranulomasPreprint
Xia, Y., Wang, J., Wang, P., Liu, X., Li, C., Ju, Y., Liu, S., Dong, Y., Wang, J., Tuohetaerbaike, B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.15.603490 · Cited by 5
“3D), aligning with prior studies ( 23, 24 ).”
Result
HIV-SEQ Reveals Global Host Gene Expression Differences Between HIV-Transcribing Cells from Viremic and Suppressed People with HIVPreprint
Frouard, J., Telwatte, S., Luo, X., Elphick, N., Thomas, R., Arneson, D. V., Roychoudhury, P., Butte, A. J., Wong, J. K., Hoh, R., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.17.629023 · Cited by 5
“Active viral replication may promote the acquisition and maintenance of cytotoxic functions by CD4+ T cells by eliciting a sustained pro-inflammatory environment, which has been shown in the context of cancer 68 as well as during influenza infection 69 .”
Asymmetric Dimethylarginine Disrupts Tumor Antigen Presentation in Breast Cancer
Li, M., Chen, Y.-L., Pearce, L. M., Hammett, A., Sharma, F. H., Miller, D. S., & Chen, K. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104482 · Cited by 4
“Macrophages have been reported to make up approximately 50% of tumor-infiltrating immune cells in both human and mouse studies [25,26], while T cells are among the most potent anti-tumor effectors [27,28].”
UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity
Laheurte, C., Boullerot, L., Ndao, B., Malfroy, M., Queiroz, L., Guillaume, P., Loyon, R., Seffar, E., Gravelin, E., Renaudin, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102196 · Cited by 5
“22,53 Because most tumors are MHC class II negative, we assume that IFN γ produced by vaccine-specific CD4 + T cells can upre-gulate HLA-DR expression in tumor cells, making them susceptible to lysis.”
Tumor immunotherapy: past, present, and future
Huang, Y., Ge, H., Zhang, Z., Liu, X., Zhong, K., Tong, A., Li, G., & Zhou, L. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002919 · Cited by 6
“It has recently been reported that CD4 + T cells are also capable of differentiating into cytotoxic CD4 + T cells, which have been observed to exert direct tumor-killing effects comparable to those of cytotoxic CD8 + T cells [ 139 ] .”
Mitochondria-targeted hybrid nanovesicles trigger immunogenic cell death and remodel tumor neutrophils for enhanced colorectal cancer immunotherapy
Tan, H., Li, N., Shu, S., Fan, Z., Deng, J., Wu, J., Xu, Z., Huang, Q., & Cao, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114242 · Cited by 4
CD4 aptamer-engineered cell platforms enhance anti-tumor immunity in triple-negative breast cancer
Tang, H., Xiong, Y., Gan, S., Fei, L., Guo, L., Zhang, K., Li, H., Fu, T., Wu, Q., & Tan, W. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100218 · Cited by 5
MHC-II-restricted neoantigen vaccine reverses immune microenvironment and overcomes resistance to immune-checkpoint inhibitors in cold tumors
Song, X., Lu, C., Shi, T., Wang, H., Liu, W., Luo, Y., Zhou, X., Wang, Y., Ren, S., Yu, L., et al. (2025) · Med · doi:10.1016/j.medj.2025.100936 · Cited by 4
In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8 + T cell responses
Wang, M., Qiu, L., Tang, C., Huang, D., Zheng, Q., Li, Z., Zhang, Z., Wei, S., Chen, L., Huang, H., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011665 · Cited by 4
A pan-cancer single-cell transcriptomic atlas of human bone metastases
Wang, S., Ma, F., Wang, D., Yu, Q., Zheng, H., Chen, Z., Zhao, S., Xu, L., Ye, Q., Tan, Y., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102583 · Cited by 7
PD1 cell membrane-coated Ru(ll)-Pt(lV) complex nanoparticles inhibit liver metastatic melanoma via cascade immune activation
Huang, C., Phann, T. T., Ouyang, F., Zhou, D., Guo, P., Wang, Y., Huang, Y., Zeng, T., Gao, Q. S., Wei, H. Z., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04167-x · Cited by 4
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma
Sperling, A. S., Derman, B. A., Nikiforow, S., Alonso, A., Ikegawa, S., Orwitz, N., Quinn, D. S., Pearson, D. E., 部德秀, Milanez‐Almeida, P., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx1799 · Cited by 4
Immunotherapies in breast cancer: harnessing the cancer immunity cycle
Lok, V. M., Olson-Mcpeek, S. K., Spiegelhoff, G., Cortez, J., Detz, D., & Czerniecki, B. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2427038 · Cited by 4
Identification and regulation of circulating tumor-TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancer
Kwek, S. S., Yang, H., Li, T. Y., Ilano, A., Chow, E. D., Zhang, L., Chang, H., Luong, D., Lea, A., Clark, M., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.177373 · Cited by 4
Self-citation
HDAC inhibitor GCJ-490A modulates tumor microenvironment and synergizes with PD-1 antibody against breast and lung cancers in syngeneic murine models
Zhang, W., He, T., Fang, K., Gao, Y., Sun, Y., Nan, F., Ding, J., Chen, Y., & Fang, Y. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01646-z · Cited by 4
Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers
Kurose, K., Sakaeda, K., Fukuda, M., Sakai, Y., Yamaguchi, H., Takemoto, S., Shimizu, K., Masuda, T., Nakatomi, K., Kawase, S., et al. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2022.09.004 · Cited by 5
Development and validation of a combined hypoxia and ferroptosis prognostic signature for breast cancer
Zhong, J., Shen, X., Zhou, J.-J., Yu, H.-P., Wang, B.-R., Sun, J., Wang, J., & Liu, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1077342 · Cited by 5
Comprehensive analysis of the role of cuproptosis-related genes in the prognosis and immune infiltration of adrenocortical Carcinoma
You, Z., He, J., & Gao, Z. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23661 · Cited by 4
“This also provides a potential target for future clinical drug development [62].”
Background
Doxorubicin-induced Immunogenic Cell Death Impairs Tumor Progression and Distant Metastasis in a 4T1 Breast Cancer Tumor Model
Cardador, C. M., de Castro, T. B., de Castro, R. J. A., Bocca, A. L., Camargo, L. C., Pacheco, T. J. A., Muehlmann, L. A., & Longo, J. P. F. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128316870240610045550 · Cited by 4
Environmental Low-Dose Radiation Activates Th1 Immunity through the Mitochondria-STING Pathway
Yao, X., Huo, W., Wang, Y., Xia, D., Chen, Y., Tang, Y., Tang, H., Yang, W., Liu, Y., Xue, J., et al. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.4c08009 · Cited by 4
Mutated DNMT3A creates a public HLADQ- binding neoantigen on acute myeloid leukemia
van der Lee, D. I., Argiro, E. M., Laan, S. N. J., Honders, M. W., de Jong, R. C. M., Struckman, N. E., Falkenburg, J. H. F., & Griffioen, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1556121 · Cited by 4
“Some CD4 T cells are also capable of directly killing HLA class II-expressing tumor cells (25).”
Molecular insights into immune evasion in head and neck squamous cell carcinomas: Toward a promising treatment strategy
Kim, H. J., JOO, B. K., BYUN, J.-S., & KIM, D.-Y. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.062207 · Cited by 4
“While immunomodulatory strategies typically focus on bolstering tumor-in ﬁ ltrating CD8+ T cell activity, CD4+ T cells also signi ﬁ cantly in ﬂ uence the TME by secreting cytokines that enhance CD8+ T cell in ﬁ ltration [115].”
A prognostic signature based on cuprotosis-related long non-coding RNAs predicts the prognosis and sensitivity to chemotherapy in patients with colorectal cancer
Li, W., Yang, G., Dong, H., Zhu, J., & Liu, T. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1055785 · Cited by 5
A Trefoil factor 3-Lingo2 axis restrains proliferative expansion of type-1 T helper cells during GI nematode infection
Ethgen, L., Pastore, C., Lin, C., Reed, D. R., Hung, L., Douglas, B. B., Sinker, D., Herbert, D. R., & Belle, N. M. (2024) · Mucosal Immunology · doi:10.1016/j.mucimm.2024.02.003 · Cited by 4
Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells
Wittling, M. C., Knochelmann, H. M., Wyatt, M. M., Rivera, G. O. R., Cole, A. C., Lesinski, G. B., & Paulos, C. M. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008715 · Cited by 4
“15 16 To date, how different forms of non-myeloablative preconditioning regimens impact the efficacy of transferred antitumor T helper cells has not been explored in a systematic manner.”
Background
Characterization of atypical T cells generated during ex vivo expansion process for T cell-based adoptive immunotherapy
Mercier‐Letondal, P., Kumar, A., Marton, C., Bonnefoy, F., Fredon, M., Boullerot, L., Dehecq, B., Adotévi, O., Godet, Y., & Galaine, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1202017 · Cited by 3
“Oh & Fong (10) reviewed current knowledge on the topic and described a cytotoxic-associated CD4+ T cell phenotypic pattern.”
Background
Intralesional injection of CpG ODNs complexed with glatiramer acetate mitigates systemic cytokine toxicities and synergistically advances checkpoint blockade efficacy
Gong, H., Griffin, J. D., Groer, C. E., Wu, X., Li, M., Abdelaziz, M. M., Xu, L., Forrest, M. L., & Berkland, C. J. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01798-9 · Cited by 3
“Even though eliciting a lower percentage of CD45 + immune cells compared with CpG alone, R4B monotherapy induced higher frequencies of activated cytotoxic T cells and effector T cells, which may indicate that these T cell subtypes are contributing to anticancer immunity [68, 69].”
Single-cell molecular communications and transcriptional regulatory dynamics of T cell immunotherapy in bladder cancer
Liu, L., Wan, X., Liu, C., Yu, C., Xue, H., Wang, J., Zhu, L., Liu, K., Chen, C., & Wang, J. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101760 · Cited by 3
Integrated analysis of polytranscriptomics reveals TNFSF ligand genes in pancreatic cancer prognosis and immune regulation
Deng, Z., Li, L., Yang, Z., Zeng, G., & Liu, R. (2025) · BMC Immunology · doi:10.1186/s12865-025-00733-4 · Cited by 5
Gallic Acid-Modified Graphene Oxide Nanocomposites Based Photothermal-Chemotherapy Enhancing Melanoma Immunotherapy
Feng, Y., Jin, W., Li, Z., Fan, G., Zhao, J., Zhu, M., Wang, S., Zhang, Y., Li, Y., & Dong, Z. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s531001 · Cited by 3
“46,47 Conversely, aberrant differentiation of CD4+ Th cells into dysfunctional subsets may lead to the secretion of immuno-modulatory cytokines such as IL-10, IL-17, and IFN-γ, which exert pleiotropic effects on immune regulation.”
Protein palmitoylation and immune regulation in pancreatic ductal adenocarcinoma: Integrating insights from cross-cancer studies
Cui, X., Li, C., Zhong, X., Sun, A., Lan, Y., & Wang, Z. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189532 · Cited by 3
CD55-displaying oncolytic vaccinia virus treated metastatic cancers by evading the effect of host innate and adaptive humoral responses
Kim, E., Yang, Y., Won, S., Lee, N., Kim, Y.-I., Shin, S.-K., Lee, S., Park, M.-J., Kim, H., Oh, K., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.043 · Cited by 3
Tumor Anti‐Angiogenesis Therapy and Its Influence on Immune Cell Function in the Tumor Microenvironment
Tang, Y., Ding, Y., Wang, L., Yang, Y., Han, Y., Zhou, P., Qu, H., Deng, K., & Xia, J. (2026) · Cancer Medicine · doi:10.1002/cam4.71769 · Cited by 3
The cellular actors of the tumor microenvironment: a single-cell atlas perspective on specialized subtypes, coordinated networks, and immunotherapy
Zhu, L., Jiang, N., & Zhang, Z. (2026) · Immunity & Inflammation · doi:10.1007/s44466-026-00043-3 · Cited by 3
“They are highly heterogeneous, can differentiate into multiple effector subsets—including Th1, Th2, Th17, and follicular helper T cells (Tfh cells)—and can even acquire direct cytotoxic activity in certain contexts [43, 44].”
Revealing the potential of necroptosis-related genes in prognosis, immune characteristics, and treatment strategies for head and neck squamous cell carcinoma
Cao, J., Wu, C., Han, Z., Liu, Z., Yang, Z., Ren, M., & Wang, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-47096-7 · Cited by 3
A comprehensive analysis of deubiquitinase USP20 on prognosis and immunity in pan‐cancer
Wang, T., Bai, Y., Dong, Y., Qin, J., Zhou, X., Wang, A., Liu, D., Li, X., Ma, Z., & Hu, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202402603r · Cited by 3
“37,38 However, neutrophils, macrophages, and DCs have been identified as potential immunosuppressive cells that contribute to immune resistance.”
Harnessing dendritic cells as immunological bridges to potentiate mRNA cancer vaccines
Wu, R., Li, H., Li, Z., Hao, K., & Tian, H. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00995b · Cited by 3
Integrating bulk and single cell sequencing data to identify prognostic biomarkers and drug candidates in HBV associated hepatocellular carcinoma
Zhong, Y., Stalin, A., Dai, Y.-S., He, Z., Yang, S., Zou, R.-Q., Zhai, A., Li, F., & Hu, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-10876-4 · Cited by 3
“Specifically, we observed reduced infiltration of cytotoxic T lymphocytes, such as B cells, CD4 + T cells, and CD8 + T cells, which are essential for directly attacking and eliminating tumor cells 36,37 .”
A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
Maggadottir, S. M., Kvalheim, G., Wernhoff, P., Sæbøe‐Larssen, S., Revheim, M.-E. R., Josefsen, D., Wälchli, S., Helland, Å., & Inderberg, E. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1031232 · Cited by 4
Response to Chemoimmunotherapy Is Associated With Expansion of Systemic Antitumor CD4+ Th1 Response in Metastatic Non–Small Cell Lung Cancer
Wespiser, M., Marguier, A., Lecoester, B., Richard, T., Boullerot, L., Malfroy, M., Kumar, A., Laheurte, C., & Adotévi, O. (2023) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000454 · Cited by 3
“Stage IV 12 (100) Immunotherapy Pembrolizumab 11 (92) Atezolizumab 1 (8) Chemotherapy Platins—pemetrexed 9 (75)”
Background
Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies
van Not, O. J., van den Eertwegh, A. J. M., Haanen, J. B. A. G., van Rijn, R. S., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers‐Sonderen, M. J., van Eijs, M. J. M., de Groot, J. B., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.03.009 · Cited by 3
Laparoscopic-Assisted Colorectal Resection Can Reduce the Inhibition of Immune Function Compared with Conventional Open Surgery: A Retrospective Clinical Study
Shi, B., Tai, Q., Chen, J., Shi, X., Chen, G., Yao, H., Mi, X., Sun, J., Zhou, G., Gu, W., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062320 · Cited by 3
“Apart from producing cytokines, different subsets of CD4+ T cell has been identified, including cytotoxic CD4+ T cells, which possess cytotoxic programs and can directly kill cancer cells [17].”
Background
Protein-rich fraction of Protaetia brevitarsis seulensis larvae induce maturation of dendritic cells and Th1-polarization: A promising adjuvant for anticancer therapy
Song, H.-Y., Park, W. Y., Han, J. M., Yoo, B.-G., Kang, B. S., & Byun, E. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105738 · Cited by 3
A molecular classification system for estimating radiotherapy response and anticancer immunity for individual breast cancer patients
Zhang, J., Li, L., Shang, H., Feng, Z., & Chao, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1288698 · Cited by 3
Validation of prognostic signature and exploring the immune-related mechanisms for NR3C2 in clear cell renal cell carcinoma
Chen, D., Yin, Z., Chen, Y., Bai, Y., You, B., Sun, Y., & Wu, Y. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-846 · Cited by 3
“And CD4 + T cells can also mediate cytotoxicity in cancer (19).”
Background
Predictive value of immediate early response 5 like (IER5L) in the prognosis and immune checkpoint blockade therapy of non-small cell lung cancer patients
Wang, N., Tan, X., Cao, S., & Liu, M. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155270 · Cited by 3
Expressions of CXCR3 and PD-1 on T cells and their clinical relevance in colorectal cancer
Wang, S., Zhang, Y., Chen, G., Zhao, P., Wang, X., Xu, B., & Yuan, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111988 · Cited by 3
A Nano‐Electro‐Platform Enabling Evolutionary Screening and Remodeling of Tumor Cells for Metastasis Inhibition
Liu, F., Sun, H. H., Liu, B., Zhang, J., Wu, C., Yan, S., Tai, C., Tong, Y., Su, R., Xiang, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202507684 · Cited by 3
Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains
Reimann, H., Moosmann, C., Schober, K., Lang, V., Verhagen, J., Zeun, J., Mackensen, A., Kremer, A. N., Völkl, S., & Aigner, M. (2023) · Immunobiology · doi:10.1016/j.imbio.2023.152720 · Cited by 2
Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic EfficacyPreprint
Keshari, S., Shavkunov, A. S., Miao, Q., Saha, A., Williams, C. D., Highsmith, A. M., Pineda, J. E., Alspach, E., Hu, K. H., Pauken, K. E., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4755484 · Cited by 3
Co-immunization with IFI35 enhances the therapeutic effect of an adenovirus vaccine against renal carcinoma
Lu, B., Chai, L., Zhang, Z., Zhao, G., Shao, Y., Zheng, Y., Jin, X. K., Zheng, J., Chai, D., & Ding, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138515 · Cited by 2
Harnessing TAGAP to improve immunotherapy for lung squamous carcinoma treatment by targeting c-Rel in CD4+ T cells
Cai, P., Sun, H., Jiang, T., Li, H., Huang, D., Hao, X., Wang, W., Xing, W., & Liang, G. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03960-1 · Cited by 2
“Cytotoxic CD4+ T cells could produce massive cytokines to enhance immunotherapy responses in cancer [22].”
Evoking the Cancer-immunity cycle by targeting the tumor-specific antigens in Cancer immunotherapy
Guo, X., Bai, J., Wang, X., Guo, S., Shang, Z., & Shao, Z. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114576 · Cited by 3
CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses
Nguyen, K. A., Liu, Z., Davies, J. S., McIntosh, C. P., Draper, L. M., Norberg, S. M., Rae, Z., Achar, S. R., Altan-Bonnet, G. Y., Zhang, L., et al. (2025) · Science Advances · doi:10.1126/sciadv.adq4297 · Cited by 4
Syngeneic CAR T cells engineered for persistent delivery of desired proteins
Newmyer, S. L., Radhakrishnan, H., Javitz, H. S., & Bhatnagar, P. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113960 · Cited by 2
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy
Mazzaschi, G., Rosati, R., D’Agnelli, S., Minari, R., Trentini, F., Tamarozzi, P., Manini, M., Ronzoni, M. Z., Dodi, A., Gnetti, L., et al. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2549240 · Cited by 2
Adaptive-like CAR-iPSC-CD4⁺ T cells outperform CD8⁺ counterparts in sustained ALL control
Guo, Q., Zhang, C., Wang, B., Iriguchi, S., Ishikawa, A., Minagawa, A., Ishii, T., Kawai, Y., & Kaneko, S. (2026) · Inflammation and Regeneration · doi:10.1186/s41232-025-00402-4 · Cited by 3
Tumor-reactive TCRs within exhausted TILs reveal cancer type-specific immune landscapes in renal cell carcinoma
Komahashi, M., Horaguchi, S., Tsuji, K., Hoshino, D., Kishida, T., Usui, K., Nakaigawa, N., Sato, S., Hamana, H., Kishi, H., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1729388 · Cited by 2
“Notably, in smaller tumors (KID001/002), TCR-T cells expressing CD4-derived TCRs demonstrated anti-tumor activity, suggesting the presence of cytotoxic CD4 + T cells (27, 28).”
CD8+ T cell exhaustion driven by metabolic reprogramming
Deng, W., Li, C., Wang, Q., Jiang, X., & Xie, Y. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04287-2 · Cited by 2
“Effector T cells arise under persistent antigen stimulation and inflammatory conditions, representing a metabolically highly active population responsible for target cell killing and cytokine secretion [11].”
Influential

Authors: Oh, D. Y., & Fong, L.
Affiliations: University of California, San Francisco (US)
Corresponding author: Fong, Lawrence
ORCID: Oh, David Y.
Fong, Lawrence
Venue: Immunity
Publisher: Elsevier BV
Published: 2021-12
Volume: 54
Issue: 12
Pages: 2701-2711
ISSN: 1074-7613 (ISSN-L)
DOI: 10.1016/j.immuni.2021.11.015
PMC: PMC8809482
OpenAlex: W4200244347
Cited by: 467
References: 73
Citations by year: 2026: 81 · 2025: 127 · 2024: 116 · 2023: 101 · 2022: 41 · 2021: 1
FWCI: 6.86
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Immunity (publishedVersion, cc-by)
PubMed (publishedVersion)
PubMed Central (acceptedVersion, cc-by)
eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders: NCI
National Institutes of Health (K08AI139375)
Prostate Cancer Foundation (R35CA253175)
Bavarian Nordic
Genentech
Parker Institute for Cancer Immunotherapy
AbbVie
Amgen
Merck
Merck KGaA
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: cytotoxic CD4+ T cells, antitumor immunity, cytotoxicity mechanism, cancer immunotherapy, infection, autoimmunity
MeSH terms: Animals, Cytotoxicity, Immunologic, Humans, Neoplasms, T-Lymphocytes, Cytotoxic, CD4-Positive T-Lymphocytes, Immunotherapy, Adoptive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks